(FRAG (NP (NN Objective)) (: :) (S (NP (NP (NN Mining)) (SBAR (S (NP (DT the) (NNS data)) (VP (VBD contained) (PP (IN within) (NP (NP (NNP Electronic) (NNP Health) (NNPS Records)) (-LRB- -LRB-) (NP (NNS EHRs)) (-RRB- -RRB-))))))) (VP (MD can) (ADVP (RB potentially)) (VP (VB generate) (NP (NP (DT a) (JJR greater) (NN understanding)) (PP (IN of) (NP (NN medication) (NNS effects)))) (PP (IN in) (NP (DT the) (JJ real) (NN world))) (, ,) (S (VP (VBG complementing) (SBAR (WHNP (WP what)) (S (NP (PRP we)) (VP (VBP know) (PP (IN from) (NP (VBN Randomised) (NN control) (NNS trials))) (PRN (-LRB- -LRB-) (NP (NNS RCTs)) (-RRB- -RRB-)))))))))) (. .))
(S (NP (PRP We)) (VP (VBP Propose) (NP (DT a) (NN text) (NN mining) (NN approach)) (S (VP (TO to) (VP (VB detect) (NP (NP (JJ adverse) (NNS events)) (CC and) (NP (NP (NN medication) (NNS episodes)) (PP (IN from) (NP (DT the) (JJ clinical) (NN text) (S (VP (TO to) (VP (VB enhance) (NP (NP (PRP$ our) (NN understanding)) (PP (IN of) (NP (NP (JJ adverse) (NNS effects)) (VP (VBN related) (PP (IN to) (NP (NNP Clozapine)))))))))))) (, ,) (UCP (NP (NP (DT the) (ADJP (RBS most) (JJ effective)) (JJ antipsychotic) (NN drug)) (PP (IN for) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (ADJP (NN treatment) (HYPH -) (JJ resistant)) (NN schizophrenia)))))) (, ,) (CC but) (VP (VBN underutilised) (PP (IN due) (PP (IN to) (NP (NP (NNS concerns)) (PP (IN over) (NP (PRP$ its) (NN side) (NNS effects)))))))))))))) (. .))
(NP (NP (NN Material) (CC and) (NNS Methods)) (: :) (S (NP (PRP We)) (VP (VBD used) (NP (NNS data)) (PP (IN from) (NP (NP (JJ de-identified) (NNS EHRs)) (PP (IN of) (NP (NP (NP (CD three) (NML (JJ mental) (NN health)) (NNS trusts)) (PP (IN in) (NP (DT the) (NNP UK)))) (-LRB- -LRB-) (NP (NP (QP (SYM >) (CD 50) (CD million)) (NNS documents)) (, ,) (NP (QP (IN over) (CD 500,000)) (NNS patients)) (, ,) (SBAR (WHNP (NP (CD 2835)) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (VBD were) (VP (VBN prescribed) (NP (NNP Clozapine))))))) (-RRB- -RRB-))))))) (. .))
(S (NP (PRP We)) (VP (VP (VBD explored) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (CD 33) (JJ adverse) (NNS effects)))) (PP (IN by) (NP (NN age) (, ,) (NN gender) (, ,) (NN ethnicity))) (, ,) (S (VP (VBG smoking) (NP (NN status) (CC and) (NN admission) (NN type)) (ADVP (NP (CD three) (NNS months)) (RB before))))) (CC and) (VP (PP (IN after) (NP (DT the) (NNS patients))) (VBD started) (NP (NNP Clozapine) (NN treatment)))) (. .))
(S (NP (PRP We)) (VP (VBD compared) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (JJ adverse) (NNS effects)))) (PP (IN with) (NP (NP (DT those)) (VP (VBN reported) (PP (IN in) (NP (DT the) (NN Side) (NML (NNPS Effects) (NNP Resource)) (PRN (-LRB- -LRB-) (NP (NNP SIDER)) (-RRB- -RRB-)))) (SBAR (WHADVP (WRB where)) (FRAG (ADJP (JJ possible)))))))) (. .))
(NP (NP (NNS Results)) (: :) (NP (NNP Sedation)) (, ,) (NP (NP (NN fatigue) (, ,) (NN agitation) (, ,) (NN dizziness) (, ,) (NN hypersalivation) (, ,) (NN weight)) (SBAR (S (NP (NN gain) (, ,) (NN tachycardia) (, ,) (NN headache) (, ,) (NN constipation) (CC and) (NN confusion)) (VP (VBD were) (PP (IN amongst) (NP (DT the) (JJS highest) (VBN recorded) (NN Clozapine))))))) (NP (NP (JJ adverse) (NN effect)) (PP (IN in) (NP (NP (DT the) (CD three) (NNS months)) (PP (VBG following) (NP (NP (DT the) (NN start)) (PP (IN of) (NP (NN treatment)))))))) (. .))
(S (NP (NP (JJR Higher) (NNS percentages)) (PP (IN of) (NP (DT all) (JJ adverse) (NNS effects)))) (VP (VBD were) (VP (VBN found) (PP (IN in) (NP (NP (DT the) (JJ first) (NN month)) (PP (IN of) (NP (NN Clozapine) (NN therapy))))))) (. .))
(S (S (VP (VBG Using) (NP (NP (DT a) (NN significance) (NN level)) (PP (IN of)) (PRN (-LRB- -LRB-) (S (NP (NN p)) (VP (SYM <) (NP (CD 0.05)))) (-RRB- -RRB-))) (PP (IN out) (NP (ADJP (JJ chi) (HYPH -) (JJ square)) (NNS tests))))) (VP (VBP show) (NP (NP (DT a) (JJ significant) (NN association)) (PP (IN between) (NP (NP (JJS most)) (PP (IN of) (NP (NP (NP (DT the) (NNS ADRs)) (PP (IN in) (NP (NP (NN smoking) (NN status)) (CC and) (NP (NN hospital) (NNS admissions))))) (CC and) (NP (NP (DT some)) (PP (IN in) (NP (NML (NN gender) (CC and) (NN age)) (NNS groups)))))))))) (. .))
(S (ADVP (RB Further)) (, ,) (S (NP (DT the) (NNS data)) (VP (VBD was) (VP (VBN combined) (PP (IN from) (NP (CD three) (NNS trusts)))))) (, ,) (CC and) (S (NP (ADJP (JJ chi) (HYPH -) (JJ square)) (NNS tests)) (VP (VBD were) (VP (VBN applied) (S (VP (TO to) (VP (VB estimate) (NP (NP (DT the) (JJ average) (NN effect)) (PP (IN of) (NP (NP (NNS ADRs)) (PP (IN in) (NP (DT each) (JJ monthly) (NN interval)))))))))))) (. .))
(FRAG (NP (NN Conclusion)) (: :) (S (NP (NP (DT A) (JJR better) (NN understanding)) (PP (IN of) (SBAR (WHADVP (WRB how)) (S (NP (DT the) (NN drug)) (VP (VBZ works) (PP (IN in) (NP (DT the) (JJ real) (NN world)))))))) (VP (MD can) (VP (VB complement) (NP (NP (JJ clinical) (NNS trials)) (CC and) (NP (NN precision) (NN medicine)))))) (. .))
